Incannex Healthcare Ltd ADR (IXHL) - Net Assets

Latest as of December 2025: $73.41 Million USD

Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) has net assets worth $73.41 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($75.01 Million) and total liabilities ($1.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $73.41 Million
% of Total Assets 97.87%
Annual Growth Rate 14.69%
5-Year Change 107.85%
10-Year Change N/A
Growth Volatility 164.63

Incannex Healthcare Ltd ADR - Net Assets Trend (2006–2025)

This chart illustrates how Incannex Healthcare Ltd ADR's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Incannex Healthcare Ltd ADR (2006–2025)

The table below shows the annual net assets of Incannex Healthcare Ltd ADR from 2006 to 2025.

Year Net Assets Change
2025-06-30 $13.39 Million +19.36%
2024-06-30 $11.22 Million -46.14%
2023-06-30 $20.82 Million -15.91%
2022-06-30 $24.76 Million +284.44%
2021-06-30 $6.44 Million +196.26%
2020-06-30 $2.17 Million +842.40%
2019-06-30 $-292.88K -3.23%
2018-06-30 $-283.71K -118.63%
2017-06-30 $-129.77K +75.17%
2016-06-30 $-522.58K -243.56%
2015-06-30 $364.01K -77.77%
2014-06-30 $1.64 Million -86.94%
2013-06-30 $12.53 Million -38.40%
2012-06-30 $20.35 Million +24.87%
2011-06-30 $16.29 Million +57.14%
2010-06-30 $10.37 Million +97.23%
2009-06-30 $5.26 Million -42.35%
2008-06-30 $9.12 Million +61.83%
2007-06-30 $5.63 Million +468.98%
2006-06-30 $990.36K --

Equity Component Analysis

This analysis shows how different components contribute to Incannex Healthcare Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 15691855900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock $20.00K 0.15%
Other Comprehensive Income $-3.12 Million -23.33%
Other Components $174.05 Million 1299.94%
Total Equity $13.39 Million 100.00%

Incannex Healthcare Ltd ADR Competitors by Market Cap

The table below lists competitors of Incannex Healthcare Ltd ADR ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Incannex Healthcare Ltd ADR's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 11,217,000 to 13,389,000, a change of 2,172,000 (19.4%).
  • Net loss of 46,885,000 reduced equity.
  • Other comprehensive income increased equity by 208,000.
  • Other factors increased equity by 48,849,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-46.88 Million -350.18%
Other Comprehensive Income $208.00K +1.55%
Other Changes $48.85 Million +364.84%
Total Change $- 19.36%

Book Value vs Market Value Analysis

This analysis compares Incannex Healthcare Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.33x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.06x to 0.33x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2006-06-30 $61.76 $3.79 x
2007-06-30 $228.76 $3.79 x
2008-06-30 $203.40 $3.79 x
2009-06-30 $95.36 $3.79 x
2010-06-30 $71.12 $3.79 x
2011-06-30 $83.07 $3.79 x
2012-06-30 $7.56 $3.79 x
2013-06-30 $3.10 $3.79 x
2014-06-30 $4.82 $3.79 x
2015-06-30 $0.90 $3.79 x
2016-06-30 $-1.00 $3.79 x
2017-06-30 $-0.12 $3.79 x
2018-06-30 $-0.15 $3.79 x
2019-06-30 $-0.08 $3.79 x
2020-06-30 $0.13 $3.79 x
2021-06-30 $0.26 $3.79 x
2022-06-30 $2.49 $3.79 x
2023-06-30 $4.06 $3.79 x
2024-06-30 $2.08 $3.79 x
2025-06-30 $11.66 $3.79 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Incannex Healthcare Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -350.18%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -54517.44%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.53x
  • Recent ROE (-350.18%) is below the historical average (-129.40%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2006 -18.07% 0.00% 0.00x 1.26x $-278.04K
2007 -15.99% 0.00% 0.00x 1.03x $-1.46 Million
2008 -11.55% 0.00% 0.00x 1.11x $-1.97 Million
2009 -59.46% 0.00% 0.00x 2.25x $-3.65 Million
2010 20.74% 9667.05% 0.00x 1.31x $1.11 Million
2011 -30.36% 0.00% 0.00x 1.32x $-6.58 Million
2012 -15.75% -4720.73% 0.00x 1.20x $-5.24 Million
2013 -87.73% -33715.93% 0.00x 1.42x $-12.25 Million
2014 -687.54% 0.00% 0.00x 4.47x $-11.42 Million
2015 -534.75% 0.00% 0.00x 13.16x $-1.98 Million
2016 0.00% -866.56% 0.27x 0.00x $-539.64K
2017 0.00% -7336.21% 0.28x 0.00x $-15.89 Million
2018 0.00% -291.24% 1.42x 0.00x $-2.14 Million
2019 0.00% -230.67% 2.27x 0.00x $-1.87 Million
2020 -148.45% -776.62% 0.14x 1.34x $-3.45 Million
2021 -126.69% -430.07% 0.27x 1.09x $-8.81 Million
2022 -41.40% -1898.02% 0.02x 1.06x $-12.73 Million
2023 -234.39% -4814.28% 0.04x 1.14x $-50.89 Million
2024 -246.37% -153824.99% 0.00x 1.52x $-28.76 Million
2025 -350.18% -54517.44% 0.00x 1.53x $-48.22 Million

Industry Comparison

This section compares Incannex Healthcare Ltd ADR's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $264,714,861
  • Average return on equity (ROE) among peers: -80.57%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Incannex Healthcare Ltd ADR (IXHL) $73.41 Million -18.07% 0.02x $38.01 Million
Aurora Cannabis Inc (ACB) $521.74 Million -329.21% 0.78x $192.24 Million
Akanda Corp (AKAN) $-2.20 Million 0.00% 0.00x $1.51 Million
Akebia Ther (AKBA) $247.62 Million -141.29% 1.60x $340.21 Million
Alkermes Plc (ALKS) $1.21 Billion -17.23% 0.43x $4.62 Billion
Amylyx Pharmaceuticals Inc (AMLX) $164.76 Million -183.14% 0.18x $1.88 Billion
Amphastar P (AMPH) $251.54 Million 4.72% 0.35x $959.02 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $208.93 Million -62.22% 17.18x $3.81 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $-44.54 Million 0.00% 0.00x $3.57 Billion
Anika Therapeutics Inc (ANIK) $85.19 Million 5.07% 0.51x $205.97 Million
ANI Pharmaceuticals Inc (ANIP) $4.62 Million -82.42% 0.27x $1.76 Billion

About Incannex Healthcare Ltd ADR

NASDAQ:IXHL USA Drug Manufacturers - Specialty & Generic
Market Cap
$52.96 Million
Market Cap Rank
#22889 Global
#4778 in USA
Share Price
$3.79
Change (1 day)
-7.33%
52-Week Range
$0.09 - $5.97
All Time High
$35.50
About

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more